Related Experiment Videos
Gene therapy for pancreatic cancer
1Second Department of Surgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. kasuya@helix.mgh.harvard.edu
Hepato-Gastroenterology
|August 9, 2001
Summary
Gene therapy offers new hope for treating pancreatic cancer, a disease with a poor prognosis. Research in rodent models and ongoing clinical trials explore strategies like antisense therapy and oncolytic viruses for improved patient outcomes.
Area of Science:
- Oncology
- Genetics
- Cancer Therapy
Background:
- Pancreatic cancer has a poor prognosis despite advances in surgery and locoregional therapies.
- Early diagnosis is challenging due to small tumor size and lack of early symptoms.
- The aggressive nature of pancreatic cancer leads to frequent metastasis.
Purpose of the Study:
- To review current gene therapy strategies for pancreatic cancer treatment.
- To highlight the potential of gene therapy in overcoming treatment resistance.
- To discuss ongoing clinical trials evaluating gene therapy efficacy in humans.
Main Methods:
- Review of preclinical studies in rodent models.
- Analysis of early-phase human clinical trials.
- Examination of various gene therapy approaches including antisense, prodrug activation, promoter gene, and oncolytic viral strategies.
Main Results:
- Gene therapy has shown promise in preclinical models of pancreatic cancer.
- Several gene therapy strategies are under active investigation in human clinical trials.
- Antisense strategies, gene-directed prodrug activation, promoter gene strategies, and oncolytic viral therapy are key areas of focus.
Conclusions:
- Gene therapy represents a promising frontier for pancreatic cancer treatment.
- Further clinical evaluation is crucial to establish the efficacy and safety of these novel approaches.
- New therapeutic strategies are urgently needed to improve outcomes for pancreatic cancer patients.